BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30216194)

  • 1. Patterns of Care and Outcomes of Elderly Esophageal Cancer Patients Not Meeting Age-based Criteria of the CROSS Trial.
    Verma V; Haque W; Zheng D; Osayande F; Lin C
    Am J Clin Oncol; 2019 Jan; 42(1):67-74. PubMed ID: 30216194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Feith M; Friess H; Weichert W; Jesinghaus M; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2019 Apr; 14(1):66. PubMed ID: 30992022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients.
    Lester SC; Lin SH; Chuong M; Bhooshan N; Liao Z; Arnett AL; James SE; Evans JD; Spears GM; Komaki R; Haddock MG; Mehta MP; Hallemeier CL; Merrell KW
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):820-828. PubMed ID: 28476435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
    Haque W; Verma V; Butler EB; Teh BS; Rusthoven CG
    Lung Cancer; 2019 Jan; 127():76-83. PubMed ID: 30642556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival.
    Koëter M; van Putten M; Verhoeven RHA; Lemmens VEPP; Nieuwenhuijzen GAP
    Acta Oncol; 2018 Sep; 57(9):1192-1200. PubMed ID: 29528262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes.
    Di Corpo M; Schlottmann F; Strassle PD; Nurczyk K; Patti MG
    J Laparoendosc Adv Surg Tech A; 2019 Aug; 29(8):989-994. PubMed ID: 31246532
    [No Abstract]   [Full Text] [Related]  

  • 9. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
    Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment mortality after definitive chemoradiotherapy versus resection for esophageal cancer.
    Jiang W; Verma V; Haque W; Moreno AC; Koshy M; Butler EB; Teh BS
    Dis Esophagus; 2020 Apr; 33(4):. PubMed ID: 31504359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.
    Vlacich G; Samson PP; Perkins SM; Roach MC; Parikh PJ; Bradley JD; Lockhart AC; Puri V; Meyers BF; Kozower B; Robinson CG
    Cancer Med; 2017 Dec; 6(12):2886-2896. PubMed ID: 29139215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base.
    Haque W; Verma V; Bernicker E; Butler EB; Teh BS
    Acta Oncol; 2018 Jun; 57(6):782-789. PubMed ID: 29188742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer.
    Faiz Z; van Putten M; Verhoeven RHA; van Sandick JW; Nieuwenhuijzen GAP; van der Sangen MJC; Lemmens VEPP; Wijnhoven BPL; Plukker JTM
    Ann Surg Oncol; 2019 Apr; 26(4):986-995. PubMed ID: 30719634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival.
    Haque W; Verma V; Butler EB; Teh BS
    Dis Esophagus; 2019 Apr; 32(4):. PubMed ID: 30052835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemoradiation Versus Upfront Esophagectomy in Clinical Stage II and III Esophageal Squamous Cell Carcinoma.
    Hsu PK; Chen HS; Liu CC; Wu SC
    Ann Surg Oncol; 2019 Feb; 26(2):506-513. PubMed ID: 30430325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy.
    Yang GQ; Mhaskar R; Rishi A; Naghavi AO; Frakes JM; Almhanna K; Fontaine J; Pimiento JM; Hoffe SE
    Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 30597022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
    Li F; Ding N; Zhao Y; Yuan L; Mao Y
    Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.